Table 2.

The fold change of cell proliferation in day 5 of each EGFR mutation compared to day 0 and IC₅₀ value of erlotinib treatment in each EGFR mutations

EGFR mutations	Fold change of cell proliferation		IC50 value (μM)
	Without EGF	With EGF	Erlotinib
pBabe	6.1 ± 0.7	7.3 ± 1.2	7.95 ± 0.4
WT	7.7 ± 1.2	11.4 ± 2.2	11.97 ± 1.8
T790M	12.0 ± 1.2	14.2 ± 1.5	15.16 ± 1.3
L858R	16.0 ± 1.6	19.3 ± 0.8	0.07 ± 0
K757E	7.5 ± 1.8	11.3 ± 3.1	24.67 ± 2.1
N808S	10.0 ± 2.3	12.1 ± 2.8	13.26 ± 5.3
R831C	7.1 ± 1.5	10.8 ± 3.2	8.47 ± 0.5
V897A	10.6 ± 2.5	12.5 ± 2.9	19.78 ± 3.3
P937L	11.3 ± 2.1	12.0 ± 1.2	12.32 ± 4.2
T940A	9.8 ± 2.3	13.2 ± 3.9	5.58 ± 0.4
M947T	9.5 ± 2.2	11.5 ± 3.2	12.3 ± 1.2

IC₅₀ values for erlotinib in EGFR mutants were calculated by using the data from Fig. 3